Steadvar — News without the noise

Privacy · Terms · About

© 2026 Steadvar. All rights reserved.

Varda Space Industries Expands Pharmaceutical Production in Orbit

ScienceTechnologyHealth5/13/2026
Share

Similar Articles

NASA Tests On-Demand IV Fluid Production System for Deep Space Missions

ScienceTechnology4/23/2026

Virgin Galactic Unveils Next-Generation Spaceship in Factory Photo

BusinessTechnology5/1/2026

India's Skyroot Aerospace Prepares for First Orbital Launch After Reaching $1.1 Billion Valuation

BusinessTechnology5/11/2026

Vast Unveils New Astronaut Flight Suit and Certified Watch for Commercial Space Station

TechnologyBusiness4/23/2026

NASA and SpaceX Target Mid-May Launch for Space Station Resupply Mission

ScienceTechnology5/8/2026

Varda Space Industries is scaling up its operations to manufacture pharmaceuticals in Earth orbit, citing improved research, funding, and lower launch costs as enabling factors. The company currently has one spacecraft in orbit and plans to launch three more this year. This approach leverages microgravity to create more uniform drug crystals, which could improve drug performance and storage.

Facts First

  • Varda Space Industries is preparing to launch three more spacecraft this year, following its current W-6 vehicle in orbit.
  • Microgravity in Earth orbit allows molecules to assemble more slowly, resulting in more uniform crystalline structures for pharmaceuticals.
  • The company plans to increase its launch cadence to seven missions next year, building on its current model of flying on SpaceX's Transporter missions.
  • Varda has raised $330 million to date and operates a new 10,000 square-foot pharmaceutical lab in El Segundo, California.
  • Potential benefits of space-manufactured drugs include more consistent dissolution, longer shelf life, and reduced side effects.

What Happened

Varda Space Industries is expanding its efforts to manufacture pharmaceuticals in microgravity. According to co-founder Delian Asparouhov, several trends have converged to enable the company's collaboration with United Therapeutics (UT). These include research conducted on the International Space Station (ISS), increased capital for space startups, and the rise of reusable rockets, which has lowered the cost and increased the frequency of space access. Varda's current W-6 spacecraft is in orbit, and the company is preparing three more vehicles for launch this year.

Why this Matters to You

Pharmaceuticals manufactured in the microgravity environment of Earth orbit could lead to more effective medications. The more uniform crystalline structures produced in space may allow drugs to dissolve more consistently in your body, potentially reducing side effects. These space-made drugs might also retain a longer shelf life and require less stringent cold storage, which could simplify how you store certain medications and possibly make them more accessible.

What's Next

Varda plans to significantly increase its operational tempo, with the company aiming to launch seven missions next year. This expanded cadence suggests the company is moving from initial demonstration phases into more regular production. The success of these upcoming launches could pave the way for broader adoption of space-based pharmaceutical manufacturing, potentially bringing these drugs to market.

Perspectives

“
Company Leadership asserts that the primary objective is to function as a pharmaceutical company that utilizes space-based operations to produce high-value materials for Earth. They emphasize that the business model integrates both the development of reentry technology and the creation of a massive internal customer base for those systems.
“
Scientific Analysts observe that microgravity serves as a controllable manufacturing variable, much like temperature or pressure, to enhance drug production. They also note that terrestrial laboratory testing in locations like El Segundo is a critical precursor to space-based applications.